Kazuyo Nakamura, Michihiro Kaya, Yuki Yanagisawa, Keisuke Yamamoto, Nana Takayashiki, Hirotoshi Ukita, Mariko Nagura, Kaori Sugiue, Mariko Kitajima, Kumi Hirano, Hiroki Ishida, Chiharu Onoda, Yutaka Kobayashi, Eiji Nakatani, Keiichi Odagiri, Takaya Suzuki
BACKGROUND: Bone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events. Zoledronic acid is contraindicated in patients with severe renal impairment (Ccr < 30 mL/min), but it is not completely known whether denosumab can be used in them. We aimed to determine the association between renal function and hypocalcemia development during denosumab treatment. METHODS: We included patients with solid cancer and bone metastases who started denosumab treatment between April 2017 and March 2019...
February 15, 2024: BMC Cancer